Background-Circulating very-long-chain saturated fatty acids (VLCSFAs) may play an active role in the origin of cardiometabolic diseases. Methods and Results-We measured 3 VLCSFAs (C20:0, C22:0, and C24:0) in plasma and erythrocytes using gasliquid chromatography among 794 incident coronary heart disease (CHD) cases who were prospectively identified and confirmed among women in the Nurses' Health Study (NHS; 1990 and among men in the Health Professionals Follow-Up Study (HPFS; 1994 . A total of 1233 CHD-free controls were randomly selected and matched to cases in these 2 cohorts. Conditional logistic regression was used to estimate hazard ratios and 95% confidence intervals. Plasma VLCSFAs were correlated with favorable profiles of blood lipids, C-reactive protein, and adiponectin in the NHS and HPFS and with fasting insulin and C-peptide levels in a nationally representative US comparison population. After multivariate adjustment for lifestyle factors, body mass index, diet, and long-chain n-3 and trans fatty acids, total VLCSFAs in plasma were associated with a 52% decreased risk of CHD (pooled hazard ratio, 0.48; 95% confidence interval, 0.32-0.72, comparing extreme quintiles; P trend <0.0001). For VLCSFAs in erythrocytes, a nonsignificant inverse trend with CHD risk was observed (pooled hazard ratio, 0.66; 95% confidence interval, 0.41-1.06, comparing extreme quintiles; P trend =0.16). 
I
t has been well recognized that fatty acids not only are energy-bearing nutrients and building blocks of lipid groups but also are able to modulate human body metabolism through various pathways such as activating peroxisome proliferator-activated receptors (PPARs), serving as signaling lipid hormones, and modulating lipid rafts. [1] [2] [3] Although the relationship of long-chain n-3 fatty acids, dietary saturated and polyunsaturated fatty acids, and trans fatty acids with coronary heart disease (CHD) has been examined, evidence for other fatty acids is sparse. Recently, several prospective investigations have consistently documented potentially beneficial associations of a unique group of very-long-chain saturated fatty acids (VLCSFAs), saturated fats with a chain length of ≥20 carbon atoms, in circulation with atrial fibrillation, diabetes mellitus, and insulin sensitivity. [4] [5] [6] Although diet is unlikely the major source of these fatty acids in the human body, 7 the VLCSFAs can be synthesized 8 and serve as essential constituents of sphingolipids that are found in cell membranes throughout the body. 9 Emerging evidence suggests that the VLCSFAs are actively involved in human metabolism and cardiovascular disease (CVD) pathogenesis through modulating peroxisome-related functionality and interplay with PPARs. 10 However, whether these fatty acids may also exert benefits on CHD is largely unknown.
Clinical Perspective on p 268
In the present analysis, we aimed to examine correlations between VLCSFAs in plasma and erythrocytes with blood lipids and other CVD risk markers in 2 cohorts of US men and women. We also aimed to evaluate prospectively the associations between the VLCSFAs and the risk of developing CHD in the cohorts. We hypothesized that the VLCSFAs would be
Nested Case-Control Study Design
Participants who provided blood samples and who were free of diagnosed cancer and CVD at the time of blood draw were eligible for the present nested case-control study. We prospectively identified incident CHD cases and selected 1 to 2 controls for each case using risk-set sampling from participants who remained free of CHD at the time of case diagnosis through 2006 in the NHS or 2008 in the HPFS. Cases and controls were matched on age (±2 years), smoking status (never, past, current: 1-14 cigarettes or ≥15 cigarettes per day), fasting status at blood draw (fasting for 10 hour or not fasting), and time of blood draw. After the exclusion of participants with missing plasma VLCSFA values, a total of 348 cases of nonfatal myocardial infarction (MI) and fatal CHD and 414 controls were available for analysis in the NHS. In the HPFS, 446 CHD cases and 819 controls were included after the same exclusions.
The study protocol was approved by the institutional review board of Brigham and Women's Hospital and the Human Subjects Committee Review Board of Harvard School of Public Health. Informed consent was obtained from the study participants.
Assessment of CHD
For both cohorts, participants who reported incident CHD on a biennial follow-up questionnaire were asked to provide medical records, which were reviewed by study physicians who were blinded to participant exposure status. Telephone interviews were conducted if medical records were not provided by the participants. Nonfatal MI cases were confirmed by use of World Health Organization criteria, which require typical symptoms plus either ECG abnormality or elevated cardiac enzyme levels. 11 Deaths were identified through reports from next of kin or postal authorities or by a search of the National Death Index. Fatal CHD was identified if CHD was listed as the cause of death on death certificates, hospital records, or autopsy reports. Fatal CHD was then confirmed by a review of hospital records or autopsy reports if CHD was listed as the underlying cause of death and if evidence of previous CHD was available from medical records. A designation of probable fatal CHD was given to cases with CHD listed as the underlying cause of death on the death certificate but no medical records concerning the death were available and no prior knowledge of CHD was indicated. For this analysis, confirmed and probable fatal CHD cases were included to maximize statistical power. Total CHD was defined as nonfatal MI and fatal CHD. Unconfirmed CHD deaths were excluded from the analysis.
Measurement of Circulating Fatty Acids
Fatty acid concentrations in plasma and erythrocytes were analyzed by gas-liquid chromatography, which has been described in detail elsewhere. 12 The concentration of each fatty acid was expressed as a percentage of the total fatty acid content. Samples of matched case-control pairs were handled identically and assayed in the same analytic run by the same technicians in random sequence. Both technicians and laboratory personnel were blinded to the case-control status of the samples. Laboratory quality-control samples were run with case-control samples. Three VLCSFAs were measured with this method in both cohorts: C20:0 (arachidic acid), C22:0 (behenic acid), and C24:0 (lignoceric acid). Total VLCSFA was defined as the sum of these 3 fatty acids. Coefficients of variation (CVs) of the assays were assessed by repeated analysis of the quality-control samples. The average intra-assay CVs for plasma VLCSFAs were 6.2% for C20:0, 7.7% for C22:0, and 7.6% for C24:0 in the NHS and 9.9%, 13.4%, and 14.6% in the HPFS, respectively. The corresponding values were 12.2%, 11.8%, and 20.0% for erythrocyte VLCSFAs in the NHS and 8.0%, 10.7%, and 12.4% in the HPFS.
Measurements of Plasma Lipids and Inflammatory Markers
Concentrations of total cholesterol, triglycerides, and high-density lipoprotein cholesterol (HDL-C) were measured with a Hitachi 911 analyzer using reagents and calibrators from Roche Diagnostics (Indianapolis, IN). Low-density lipoprotein cholesterol levels were determined with a homogenous direct method from Genzyme (Cambridge, MA). High-sensitivity C-reactive protein was measured with a latex-enhanced immunoturbidimetric assay from Denka Seiken (Tokyo, Japan) on a Hitachi 911 system. Soluble tumor necrosis factor-α receptor 1 and 2 and interleukin-6 levels were measured with ELISAs from R&D Systems (Minneapolis, MN). Hemoglobin A 1c (HbA 1c ) was measured by turbidimetric immunoinhibition using packed red cells (Roche Diagnostics). Total adiponectin was measured by competitive radioimmunoassay (Linco Research Inc, St. Charles, MO). CVs were generally <10% for these assays.
Assessment of Covariates
Information on the occurrence of major chronic diseases, medical history, and major lifestyle risk factors for CHD was collected at baseline and updated biennially with follow-up questionnaires in both cohorts. Body mass index (BMI) was calculated as weight divided by height squared (kg/m 2 ). Physical activity was expressed as metabolic equivalents per week using the duration of moderate or vigorous forms of exercise multiplied by the intensity of the activity. 13 History of hypertension, hypercholesterolemia, diabetes mellitus, and family history of MI were based on self-reports. Dietary variables were estimated with validated food frequency questionnaires inquiring about intake over the previous year. The alternate Healthy Eating Index score was calculated to measure overall diet quality. 14 We primarily used covariates assessed in 1990 for NHS and 1994 for HPFS for the present analyses. To minimize missing data of covariates, we carried forward values obtained in previous questionnaires. plasma, we converted units from micromoles per liter to percent of total fatty acids.
To estimate the association between VLCSFAs and risk of CHD, we used conditional logistic regression. In nested case-control studies with risk-set sampling, odds ratios derived from conditional logistic regression are unbiased estimates of hazard ratios (HRs). Participants were categorized into quintiles based on the distribution of VLCSFAs among controls. Models were adjusted for matching factors and BMI, physical activity, alcohol use, parental history of MI before 65 years of age, menopausal status and hormone use (NHS only), use of aspirin, alternate Healthy Eating Index score, and history of hypercholesterolemia, diabetes mellitus, or hypertension. Models were further adjusted for circulating plasma or erythrocyte long-chain n-3 and trans fatty acids. Tests for linear trend were done by treating the median value for each quintile of VLCSFAs as a continuous variable. Associations were modeled separately for each cohort, and the HRs from the final model for each cohort were pooled to obtain a summary risk estimate using a fixed-effects meta-analysis because tests for heterogeneity were not significant for most associations. To assess the dose-response relationship between plasma and erythrocyte levels of total VLCSFAs and risk of CHD, we used spline regression with 3 knots. Study participants with the highest 1% of fatty acid levels were excluded to minimize the potential impact of outliers. Lastly, given the potential interplay between VLCSFAs and PPARδ, 16 we explored in a post hoc analysis the interactions between singlenucleotide polymorphisms in the PPARD region and VLCSFAs on CHD risk. This analysis was based on existing data from genomewide association studies of CHD in the 2 cohorts. Details of study design, genotyping, and single-nucleotide polymorphism imputation methods were published elsewhere. 17 All P values were 2-sided, and 95% confidence intervals were calculated for HRs. Data were analyzed with the Statistical Analysis Systems software package, version 9.1 (SAS Institute, Inc, Cary, NC).
Results
Baseline characteristics of CHD cases and controls from both cohorts are shown in Table 1 . Men and women with diagnosed CHD had a significantly higher BMI, had a lower intake of alcohol, and were more likely to have a family history of MI, hypercholesterolemia, hypertension, diabetes mellitus, an unfavorable lipid profile, and elevated levels of inflammatory markers and HbA 1c compared with controls. There were no significant differences in circulating erythrocyte VLCSFAs between cases and controls. However, levels of plasma VLCSFAs, especially C24:0, were lower in cases than in controls in both cohorts.
Within each compartment (plasma or erythrocytes), individual VLCSFAs were correlated with each other, whereas the correlations between plasma and erythrocyte VLCSFAs were generally much weaker (Table I in the online-only Data Supplement). Interestingly, for plasma VLCSFAs, there was a gradient in the strength of correlation with long-chain n-3 and trans fatty acids by chain length of VLCSFAs: Plasma VLCSFAs with a longer chain tended to be more strongly correlated with increased levels of long-chain n-3 but decreased levels of trans fatty acids in plasma. No such pattern was observed for fatty acids in erythrocytes.
In cross-sectional analyses adjusted for age at blood draw, smoking status, fasting status, time of blood draw, BMI, alcohol intake, physical activity (metabolic equivalents per week), and Alternate Healthy Eating Index score, plasma total VLCSFAs were significantly correlated with higher HDL-C levels (r s =0.28 and 0.32), lower triglyceride levels (r s =−0.44 and −0.58), and higher total adiponectin levels (r s =0.15 and 0.21) in the HPFS and NHS, respectively (Table II in the online-only Data Supplement). In NHS, these fatty acids were also inversely correlated with C-reactive protein levels (r s =−0.15 to −0.17). In contrast, correlations between erythrocyte VLCSFAs and CVD risk markers were generally weaker and nonsignificant except for correlations between erythrocyte C20:0 and triglyceride levels in both cohorts. In the NHANES sample, strong inverse correlations were also observed between plasma VLCSFAs and fasting triglyceride levels (r s =−0.57 to −0.66), whereas positive correlations between these fatty acids and HDL-C levels were observed largely among men only (r s =0.25-0.31; Table III in the onlineonly Data Supplement). In addition, we found significant inverse correlations between VLCSFAs and fasting insulin primarily in women (r s =−0.17 to −0.19) and with C-peptide in both men and women (r s =−0.12 to −0.24) in NHANES.
Baseline characteristics according to level of total VLCSFAs in controls are shown in Table IV in the onlineonly Data Supplement. Overall, higher plasma VLCSFAs were correlated with a low risk profile such as younger age, lower BMI, and lower trans fat intake. In crude models adjusted for matching factors, plasma VLCSFAs were associated with lower CHD risk in men and women (Table V in the online-only Data Supplement). After further adjustment for BMI, medical history, lifestyle, and diet, these associations were attenuated but still statistically significant. Additional adjustment for circulating long-chain n-3 and trans fatty acids did not attenuate the associations further (Table 2) . When the extreme quintiles of total plasma VLCSFAs were compared, the pooled HR was 0.49 (95% confidence interval, 0.32-0.72; P for trend<0.0001). In contrast, total erythrocyte VLCSFAs were associated with a lower CHD risk in women only (Table 3) , with nonsignificant inverse trends in men and overall. These associations did not change materially when we used a random-effects model to pool the results. For example, the pooled HR was 0.48 (95% confidence interval, 0.31-0.73; P for tend=0.01) when extreme quintiles of total plasma VLCSFAs were compared. When we further adjusted for blood lipids, C-reactive protein, and HbA 1c levels, the associations for plasma VLCSFAs were modestly attenuated to 0.60 (95% confidence interval, 0.36-1.00; P for trend=0.08).
In cubic spline regression analysis, per 1-SD increment, total plasma VLCSFAs were associated with a 10% (95% confidence interval, 1-18) lower CHD risk, with evidence for a monotonic relationship (P for linearity=0.03) and little evidence for nonlinearity (P for curvature=0.84; Figure) . In similar analyses, erythrocyte VLCSFAs were not significantly associated with CHD.
In the post hoc analysis, plasma VLCSFAs were more strongly associated with lower CHD risk among participants who were homozygous carriers of major alleles of rs3798343 or rs9380506 in the PPARD region ( Figure ; HDL-C, high-density lipoprotein cholesterol; HPFS, Health Professionals Follow-Up Study; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; LDL-C, low-density lipoprotein cholesterol; MET, metabolic equivalent of task; MI, myocardial infarction; NHS, Nurses' Health Study; TC, total cholesterol; TG, triglyceride; and TNF-R, tumor-necrosis factor receptor.
*Values are mean (SD) for continuous variables or percent for categorical variables. ‡Matching factors. §Among postmenopausal women only. ‖Glycemic load was calculated as the product of amount of carbohydrate and glycemic index for a given food. Then glycemic loads from all food items were summed to represent the glycemic load of the whole diet.
¶In the HPFS, n=1261 for LDL-C, hsCRP, and erythrocyte very-long-chain fatty acids; 1262 for TG, TC, and HDL-C; 1258 for HbA 1c ; and 755 for TNF-R1, TNF-R2, and IL-6. In the NHS, n=690 for C20:0 and C22:0 in erythrocytes; 618 for C24:0 in erythrocytes; 748 for TC and HDL-C; 739 for LDL-C; 730 for TG; 742 for hsCRP; 310 for TNF-R1 and TNF-R2; 300 for IL-6; and 652 for HbA 1c . 
Discussion
In this prospective investigation, we found that plasma levels of VLCSFAs were correlated with a favorable profile of blood lipids, insulin resistance markers, and inflammatory markers in men and women and in a nationally representative US population. In addition, these fatty acids were significantly associated with a lower CHD incidence in our cohorts. These associations were independent of established demographic, lifestyle, dietary, and circulating long-chain n-3 and trans fatty acids. In contrast, although erythrocyte VLCSFAs were also correlated with a favorable profile of blood lipids, they were not associated with CHD incidence after multivariate adjustment.
Our observation of an inverse association between plasma VLCSFAs and CHD risk is in line with results from a few prospective investigations published fairly recently that examined blood concentration of VLCSFAs in relation to various cardiometabolic conditions. In the Cardiovascular Health Study (CHS) consisting of 2899 elderly participants, VLCSFAs in serum were significantly associated with a lower CHD indicates coronary heart disease; CI, confidence interval; HPFS, Health Professionals Follow-Up Study; HR, hazard ratio; NHS, Nurses' Health Study; and VLCSFA, very-long-chain saturated fatty acid.
*Multivariate analysis was adjusted for the matching factors, that is, age at blood draw; smoking status (never, past, current); fasting status (yes, no) and time of blood draw; body mass index (kg/m 2 ); physical activity (metabolic equivalents per week); alcohol use (abstainer, <5.0, 5.0-14.9, ≥15.0 g/d); parental history of myocardial infarction before 65 years of age (yes, no); menopausal status and hormone use (premenopausal, current user, past user, and nonuser; NHS only); use of aspirin (yes, no); Alternate Healthy Eating Index score; history of hypercholesterolemia, diabetes mellitus, or hypertension (yes, no); and plasma trans fatty acids and long-chain n-3 fatty acids.
†Based on a fixed-effect model. The test for heterogeneity was based on the Cochran Q statistic. ‡P for heterogeneity<0.05.
by guest on April 21, 2017 http://circ.ahajournals.org/ Downloaded from risk of developing atrial fibrillation. 6 In a small nested casecontrol study of diabetes mellitus conducted in Australia, C24:0 in whole blood was significantly associated with a lower incidence of diabetes mellitus. 5 Results for C20:0 and C22:0 were not available in this analysis. In the much larger European Prospective Investigation into Cancer and Nutrition (EPIC)-InterAct case-cohort study, VLCSFAs in plasma phospholipids were all inversely associated with a lower risk of type 2 diabetes mellitus. 4 In contrast to prospective results, evidence generated from cross-sectional studies has been somewhat mixed. Our findings of strong inverse correlations between VLCSFAs and CVD or diabetes risk markers were also observed in some cross-sectional studies. For example, in healthy adolescent girls, plasma C24:0 was the only individual fatty acid that was positively correlated with adiponectin levels. 18 In Japanese men ≥40 years of age, serum levels of both C22:0 and C24:0 were correlated with higher HDL-C levels and lower triglyceride levels. 10 However, in 2 other cross-sectional studies, VLCSFA levels in serum or whole blood were positively associated with coronary artery disease prevalence or insulin resistance. 19, 20 Evidence on erythrocyte VLCSFAs is sparse and exclusively from cross-sectional Hazard ratio of coronary heart disease (95% confidence interval [CI]) by levels of total very-long-chain saturated fatty acids in US men and women. Study participants with the highest 1% of fatty acid levels were excluded to minimize the potential impact of outliers. Multivariate conditional logistic regression models were adjusted for the same set of covariates listed in the footnote of Table 2 . The solid line represents hazard ratios; shaded areas represent the 95% CIs. The horizontal line is the reference, and vertical lines represent the cutoff points for making quintiles. A, Plasma; B, erythrocytes. studies. Interestingly, in these studies, erythrocyte C24:0 or C26:0 was consistently correlated with atherogenic lipoprotein profiles or diabetes status. [21] [22] [23] The source of heterogeneity among these cross-sectional studies is unknown, although they all shared similar limitations such as small sample size and lack of adequate control for covariates.
The mechanisms underlying these observations are not well established, although evidence from animal experiments suggests that these fatty acids may actively modulate lipid metabolism and insulin sensitivity through multiple pathways. Unlike most other fatty acids that are oxidized in mitochondria, the β-oxidation of very-long-chain fatty acids occurs primarily in peroxisomes. 24 Activated fatty acid-CoA can be used in anabolic processes in peroxisomes, including the synthesis of plasmalogen. 25 In fact, in various peroxisomal disorders, including Zellweger syndrome, Resfum disease, and X-linked adrenoleukodystrophy, elevated levels of VLCSFAs are accompanied by defects in plasmalogens. 25, 26 Plasmalogens may serve as antioxidants by being preferentially oxidized to spare the oxidation of other ); physical activity (metabolic equivalents per week); alcohol use (abstainer, <5.0, 5.0-14.9, ≥15.0 g/d); parental history of myocardial infarction before 65 years of age (yes, no); menopausal status and hormone use (premenopausal, current user, past user, and nonuser; NHS only), use of aspirin (yes, no); Alternate Healthy Eating Index score; history of hypercholesterolemia, diabetes mellitus, or hypertension (yes, no); and erythrocyte trans fatty acids and long-chain n-3 fatty acids.
†Based on a fixed-effect model. The test for heterogeneity was based on Cochran's Q statistic.
by guest on April 21, 2017 http://circ.ahajournals.org/ Downloaded from lipids. 25 Another unique feature that distinguishes VLCSFAs from other fatty acids is that PPARα does not play a pivotal role in regulating the β-oxidation of VLCSFAs. 27, 28 Instead, PPARδ may modulate the metabolism of very-long-chain fatty acids by upregulating very-long-chain acyl-CoA synthetase, 16 which is localized in peroxisome membranes and plays an essential role in activating VLCSFAs to facilitate downstream processes. 29, 30 Our observations of strong favorable correlations between VLCSFAs and blood lipids, as well as insulin resistance, are in line with the effects of PPARδ activation on raising HDL-C levels, reducing triglyceride levels, and improving insulin sensitivity. 31 We also observed potential interactions between VLCSFAs and PPARD variants, although the post hoc nature of this analysis precludes any causal interpretation and the biology concerning any reciprocal relationship between circulating VLCSFAs and PPARδ functionality needs to be established. Lastly, the associations of interest were weaker for erythrocyte membrane levels than for plasma levels of VLCSFAs in the present study. Compared with plasma, erythrocyte membranes may serve as a secondary pool of these fatty acids, which have to be released into circulation through phospholipid exchange mechanisms to exert subsequent effects in tissues or organs. 32 The present analysis is subject to a few limitations. First, study participants in the NHS and HPFS are primarily white healthcare professionals. Although the homogeneity of socioeconomic status and ethnicity helps control for confounding, the inverse associations between plasma VLCSFAs and CHD risk may not be generalizable to populations with other characteristics. However, favorable correlations between these fatty acids and blood lipids and insulin resistance markers were also observed in a nationally representative US sample. Second, although we adjusted for lifestyle, diet, medical history, and other fatty acids, we cannot exclude the role of residual or unmeasured confounding in the findings. Lastly, the CVs of plasma fatty acids were somewhat higher in HPFS than in NHS, and most of the erythrocyte VLCSFAs had CVs >10% in both cohorts. In general, measurement error, when not related to outcome ascertainment, tends to bias the associations toward the null.
Conclusions
Plasma VLCSFAs were correlated with improved blood lipid profiles and insulin resistance markers in 2 prospective case-control studies of US men and women and in a sample of NHANES participants. In addition, these fatty acids were associated with lower CHD risk in our study populations. These associations were independent of established and potential CVD risk factors, including age, smoking, alcohol use, BMI, and diet. Although the present investigation, along with prior studies, suggests a potential link between these fatty acids and cardiometabolic diseases, much research is needed to elucidate the mechanisms underlying the observed associations. In addition, future studies should be conducted to explore factors that may modulate levels of these unique fatty acids, which may have potential value as targets for public health prevention or clinical intervention of heart disease.
CLINICAL PeRSPeCTIVe
Very-long-chain saturated fatty acids (VLCSFAs) are saturated fats with a chain length of ≥20 carbon atoms. In the human body, unlike most other fatty acids, these saturated fatty acids are oxidized in peroxisomes and may subsequently interact with peroxisome proliferator-activated receptor-δ to exert beneficial effects on modulating blood lipids and insulin resistance. Limited human data have demonstrated inverse associations between circulating VLCSFAs and cardiometabolic diseases, including diabetes mellitus and atrial fibrillation, although no data exist on VLCSFA levels in relation to incident coronary heart disease. In the present study, we measured blood levels of 3 VLCSFAs (C20:0, C22:0, and C24:0) in 2 prospective case-control studies in the Nurses' Health Study and Health Professionals Follow-Up Study cohorts. In these 2 cohorts and a nationally representative US comparison population, plasma levels of VLCSFAs were strongly correlated with a favorable profile of blood lipids, inflammatory markers, and markers of insulin sensitivity. Consistent with these observations, VLCSFAs in plasma were significantly associated with a lower risk of developing coronary heart disease in the 2 cohorts. Although more data are needed to corroborate these observations and to further elucidate mechanisms underlying the associations, our study provides novel evidence suggesting that these fatty acids may play an important role in the origin of coronary heart disease. Overall, these data suggest that the VLCSFAs may serve as a promising target for public health prevention and clinical intervention.
Supplemental Material
Supplementary Table 1. Partial Spearman correlation coefficients* among plasma and erythrocyte VLCSFAs, long-chain n-3 fatty acids, and trans fatty acids among controls in the HPFS (n=816) and NHS (n=329). Plasma Erythrocytes C20:5n-3 † C22:5n-3 † C22:6n-3 † trans-18:1 isomers † Total trans isomers † C20:0 C22:0 C24:0 C20:0 C22:0 C24:0 Plasma HPFS C20:0 BMI, body mass index; MET, metabolic equivalent of task; AHEI, alternative healthy eating index; VLCFA, very-long chain fatty acid. *Partial correlation coefficients were adjusted for age at blood draw (yr), smoking status (never, past, current), fasting status (yes, no), time of blood draw, BMI (kg/m 2 ), alcohol intake (abstainer, <5.0, 5.0-14.9, ≥15.0 g/day), physical activity (METs-hr/week), and AHEI score. †Correlation coefficients were calculated among fatty acids in the same compartment (either plasma or erythrocytes). BMI, body mass index; MET, metabolic equivalent of task; MI, myocardial infarction; AHEI, alternative healthy eating index; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triacylglycerol; hsCRP, high-sensitivity C-reactive protein; TNF-R, tumor-necrosis factor receptor; IL-6, interleukin-6; HbA1c, hemoglobin-A1c; VLCFA, very-long chain fatty acid. current analysis, we excluded NHANES participants with self-reported CVD, diabetes, or cancer, and correlation coefficients were adjusted for age (yr), ethnicity (non-Hispanic white, non-Hispanic black, Mexican American, other Hispanic groups, and other ethnicity), educational attainment (high school and below, college, and graduate school), BMI (kg/m2), smoking status (never, past, current), alcohol intake (abstainer, 1 drink/day, 2+ drinks/day), and physical activity (engage in vigorous activities or not).
Supplementary

†NHANES participants with self-reported cardiovascular disease, diabetes, or cancer were excluded from analysis. ‡P<0.05 §P<0.00056 (0.05/90 comparisons). †Based on model 1, model 2 was further adjusted for body mass index (kg/m 2 ), physical activity (METs-hr/week), alcohol use (abstainer, <5.0, 5.0-14.9, ≥15.0 g/day), parental history of MI before age 65 years (yes, no), menopausal status and hormone use (premenopausal, current user, past user, and non-user; NHS only), use of aspirin (yes, no), AHEI score, and history of hypercholesterolemia, diabetes, or hypertension (yes, no).
